Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Signoretti

Showing results (91-100 of 257) with videos related to

Pageof 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR TrialThomas Denize, Subrina Farah, Alessia Cimadamore, et al.
Plos Genetics|September 27, 2018
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinomaLana Hamieh, Toni K Choueiri, Barbara Ogórek, et al.
Cancer Discovery|August 17, 2012
Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cellsHanna S Kuznetsov, Timothy Marsh, Beth A Markens, et al.
Genome Biology|August 24, 2016
Comprehensive analyses of tumor immunity: implications for cancer immunotherapyBo Li, Eric Severson, Jean-Christophe Pignon, et al.
Nature Medicine|January 9, 2018
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanismsMarco Bezzi, Nina Seitzer, Tomoki Ishikawa, et al.
Nature|September 6, 2016
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsHyejin Cho, Xinlin Du, James P Rizzi, et al.
JAMA Oncology|May 30, 2020
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical TrialToni K Choueiri, Daniel Y C Heng, Jae Lyun Lee, et al.
BMC Cancer|August 8, 2021
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinomaThomas Powles, Toni K Choueiri, Robert J Motzer, et al.
Urologic Oncology|March 15, 2011
RET protein expression in papillary renal cell carcinomaRichard Flavin, Stephen P Finn, Toni K Choueiri, et al.
Molecular Cancer Research : MCR|September 4, 2014
RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinomaSumanta K Pal, Miaoling He, Tommy Tong, et al.
Pageof 26

Showing results (91-100 of 257) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR TrialThomas Denize, Subrina Farah, Alessia Cimadamore, et al.
Plos Genetics|September 27, 2018
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinomaLana Hamieh, Toni K Choueiri, Barbara Ogórek, et al.
Cancer Discovery|August 17, 2012
Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cellsHanna S Kuznetsov, Timothy Marsh, Beth A Markens, et al.
Genome Biology|August 24, 2016
Comprehensive analyses of tumor immunity: implications for cancer immunotherapyBo Li, Eric Severson, Jean-Christophe Pignon, et al.
Nature Medicine|January 9, 2018
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanismsMarco Bezzi, Nina Seitzer, Tomoki Ishikawa, et al.
Nature|September 6, 2016
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsHyejin Cho, Xinlin Du, James P Rizzi, et al.
JAMA Oncology|May 30, 2020
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical TrialToni K Choueiri, Daniel Y C Heng, Jae Lyun Lee, et al.
BMC Cancer|August 8, 2021
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinomaThomas Powles, Toni K Choueiri, Robert J Motzer, et al.
Urologic Oncology|March 15, 2011
RET protein expression in papillary renal cell carcinomaRichard Flavin, Stephen P Finn, Toni K Choueiri, et al.
Molecular Cancer Research : MCR|September 4, 2014
RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinomaSumanta K Pal, Miaoling He, Tommy Tong, et al.
Pageof 26